Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem Buys 69,686 Shares

Inhibrx, Inc. (NASDAQ:INBX) Director Jon Faiz Kayyem purchased 69,686 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Inhibrx Price Performance

NASDAQ:INBX opened at $14.08 on Friday. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95. The business has a fifty day moving average of $15.61 and a 200-day moving average of $17.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its stake in shares of Inhibrx by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after purchasing an additional 1,112 shares in the last quarter. Black Maple Capital Management LP bought a new position in Inhibrx during the first quarter valued at about $555,000. Finally, Alpine Global Management LLC acquired a new position in Inhibrx during the first quarter worth about $1,224,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.